In the US prospective Neoadjuvant Breast Symphony Trial study enrolling 608 evaluable patients, the probability of pCR was decreased when tumor size was more than 5 cm, particularly in the Basal and HER2 subtypes. Here, ERBB2 is linked to neoplasm.